CJC- 1295, (or CJC DAC) developed by ConjuChem, is a long acting analog of Growth – hormone- releasing- hormone (GHRH). GHRH, also known as somatocrinin is a peptide hormone composed of 44 amino acids. It is produced by the arcuate nucleus in the hypothalamus.
CJC 1295 is the synthetic modification of GRF and contains D- Ala, GLN, Ala, and Leu substituent at positions 2, 8, 15, and 27 respectively. The substituents are responsible for a more stable peptide with substitutions on different positions. Substitutions have been done on:
- Position 2 to prevent cleavage of DPP- IV,
- Position 8 to help reducing rearrangement of asparagines or the hydrolysis of amide to aspartic acid,
- Position 15 enhancing bioactivity,
- Position 27 preventing methionine oxidation
CJC- 1295 has the ability to bio-conjugate with serum albumin hence increasing its half life as well as therapeutic window. This is achieved by the presence of protecting groups around the amino acid. These protecting groups help to prevent enzymatic degradation. The half life in this case is increased from a mere 7 minutes to an incredible 7 days.
The technology (bio-conjugation) has managed to achieve success by taking reactive groups and attach them to a peptide which then reacts with nucleophilic (such as albumin) entities in the blood to produce a very stable bond. Bio-conjugation was shown to be so effective that less than 1% of CJC- 1295 was left un-reacted in vivo. More than 90% of CJC- 1295 was shown to be stable after being injected subcutaneously.
Moreover, no amount of DPP- IV degraded on CJC- 1295 in any of the conducted experiments. A good number of experiments have been carried out to study the effectiveness of CJC- 1295 in vivo. The journal of clinical; endocrinology and metabolism has reported that the dose – dependent to increases mean plasma GH concentrations by about 2 to 10 folds for about 6 to 7 days. An increased concentration of IGF- 1, (about 1.5 to 3 folds) was also detected for an average of 10 days following the injection.
The study also found out that following the subcutaneous injection, there was sustained, dose- dependent increase in GH and IGF- I in a healthy individual. It was also shown to be safe and well tolerated relatively and more particularly at doses between 30 and 60 micrograms per kg. Cumulative effects were also evident following multiple CJC 1295 doses.
No adverse reactions were observed in the studies and it was shown that the mean IGF- 1 levels remained over the baseline for up to 28 days after multiple doses. Because of the long half life, it need be taken just ones or twice a week.
In conclusion, the developed to treat visceral fat deposits in AIDS patients who are obese was shown to work so well that almost no complains are heard of.
*This article was contributed by Brady Gonzalez and is not the opinion of US Peptides. US Peptides sells research peptides for research purposes only and is not for human consumption.